The Market Analyzer
  • Business
  • Investing
  • Economy
  • Stock
Trending Now
Breakouts, Momentum & Moving Averages: 10 Must-See Stock...
Hedge Market Volatility with These Dividend Aristocrats &...
S&P 500 Bullish Patterns: Are Higher Highs Ahead?
Strategic Chaos or Tactical Goldmine? What QQQ’s Chart...
Why ADX Can Mislead You — And How...
S&P 500 on the Verge of 6,000: What’s...
Wildfires Slash Canadian Oil Output by 7 Percent
Top 9 Nickel-producing Countries
Scoping Study Demonstrates Low Cost ISR Uranium Potential
Satellite Imagery and Gold Exploration

The Market Analyzer

  • Business
  • Investing
  • Economy
  • Stock
Business

Elon Musk’s Neuralink raises $650 million in fresh capital

by admin June 4, 2025
June 4, 2025
Elon Musk’s Neuralink raises $650 million in fresh capital

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS

previous post
Tesla’s robotaxi launch in tech-friendly Austin has Musk playing catch-up in his hometown
next post
Crypto Market Recap: Trump’s Truth Social Moves to Launch Spot Bitcoin ETF

Related Posts

YouTube will stream NFL Week 1 game in...

May 15, 2025

Walgreens doubles down on prescription-filling robots to cut...

May 13, 2025

Uber delivery chief Gore-Coty is leaving after almost...

June 4, 2025

McDonald’s Snack Wrap is officially making a permanent...

June 5, 2025

Nvidia results spark global chip rally

May 30, 2025

Temu halts shipping direct from China as de...

May 5, 2025

McDonald’s announces plan to hire 375,000 employees this...

May 14, 2025

Boeing to resume airplane deliveries to China next...

May 30, 2025

Fortnite applies to launch on Apple’s App Store...

May 12, 2025

Why Trump’s iPhone tariff threat might not be...

May 25, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Breakouts, Momentum & Moving Averages: 10 Must-See Stock Charts Right Now
    • Hedge Market Volatility with These Dividend Aristocrats & Sector Leaders
    • S&P 500 Bullish Patterns: Are Higher Highs Ahead?
    • Strategic Chaos or Tactical Goldmine? What QQQ’s Chart is Whispering Right Now
    • Why ADX Can Mislead You — And How to Avoid It

    Popular Posts

    • 1

      Stock Market News UK Update: FTSE 100 & 250 Rise

      April 16, 2025
    • 2

      Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

      April 21, 2025
    • 3

      Stock Market News UK Update: FTSE 100 & 250 Rise

      April 17, 2025
    • 4

      Stock Market News UK Update: FTSE 100 & 250 Rise

      April 17, 2025
    • 5

      Stock Market News UK Update: FTSE 100 & 250 Rise

      April 20, 2025

    Categories

    • Business (71)
    • Economy (20)
    • Investing (281)
    • Stock (131)
    Footer Logo
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: themarketanalyzer.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 themarketanalyzer.com | All Rights Reserved